WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc. (NYSE: PKI), a global leader focused on improving the health
and safety of people and the environment, today announced the expiration
of the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and clearance under Germany's Act against
Restraints of Competition (which was granted on October 10, 2011), in
connection with its previously announced acquisition of Caliper Life
Sciences, Inc. Completion of the transaction remains subject to the
satisfaction of certain conditions, including approval of the
stockholders of Caliper Life Sciences.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow and revenue growth
and other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities and
divestitures. Words such as "believes," "intends," "anticipates,"
"plans," "expects," "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's
current assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets into
which we sell our products declining or not growing as anticipated; (2)
fluctuations in the global economic and political environments; (3) our
failure to introduce new products in a timely manner; (4) our ability to
execute acquisitions and license technologies, or to successfully
integrate acquired businesses and licensed technologies into our
existing business or to make them profitable, or successfully divest
businesses; (5) our failure to adequately protect our intellectual
property; (6) the loss of any of our licenses or licensed rights; (7)
our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package
delivery and import/export services or significant increases in prices
for those services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance with
applicable government regulations; (13) regulatory changes; (14) our
failure to comply with healthcare industry regulations; (15) economic,
political and other risks associated with foreign operations; (16) our
ability to retain key personnel; (17) significant disruption in our
information technology systems; (18) restrictions in our credit
agreements; (19) our ability to realize the full value of our intangible
assets; (20) significant fluctuations in our stock price; (21) reduction
or elimination of dividends on our common stock; and (22) other factors
which we describe under the caption "Risk Factors" in our most recent
quarterly report on Form 10-Q and in our other filings with the
Securities and Exchange Commission. We disclaim any intention or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies
enabling researchers in the life sciences industry to create life-saving
and enhancing medicines and diagnostic tests more quickly and
efficiently. Caliper is aggressively innovating new technology to bridge
the gap between in vitro assays and in vivo results, enabling the
translation of those results into cures for human disease. Caliper's
portfolio of offerings includes state-of-the-art microfluidics, lab
automation and liquid handling, optical imaging technologies, and
discovery and development outsourcing solutions. For more information
please visit www.caliperLS.com.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $1.7 billion in 2010, has about 6,200 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Important additional information filed with the SEC and distributed
to shareholders of Caliper Life Sciences.
Caliper Life Sciences has filed with the SEC and mailed to its
shareholders a Definitive Proxy Statement on Schedule 14A pursuant to
Section 14(a) of the Exchange Act in connection with the transaction. This
document contains important information about PerkinElmer, Inc., Caliper
Life Sciences, the transaction and other related matters. Caliper Life
Sciences' investors and security holders are urged to read this document
carefully.
Caliper Life Sciences' investors and security holders will be able to
obtain free copies of the Definitive Proxy Statement and other documents
filed with the SEC by Caliper Life Sciences through the web site
maintained by the SEC at www.sec.gov.
Caliper Life Sciences and its directors and executive officers may be
deemed to be participants in the solicitation of proxies in respect of
the transactions contemplated by the merger agreement. Information
regarding Caliper Life Sciences' directors and executive officers is
contained in Caliper Life Sciences' Form 10-K for the year ended
December 31, 2010 and its proxy statement dated April 26, 2011, which
are filed with the SEC. Caliper Life Sciences' proxy statement dated
April 26, 2011 also contains information regarding the beneficial
ownership of Caliper Life Sciences stock by Caliper Life Sciences'
directors and executive officers. In addition, outstanding stock options
and restricted stock units held by directors, executive officers and
other employees of Caliper Life Sciences will be accelerated in
connection with the transactions contemplated by the merger agreement. A
more complete description is available in the Definitive Proxy Statement.
PerkinElmer, Inc.
Investor Relations:
David C.
Francisco, 781-663-5677
Vice President, Investor Relations
dave.francisco@perkinelmer.com
or
Media
Contacts:
Stephanie R. Wasco, 781-663-5701
Vice President,
Corporate Communications
stephanie.wasco@perkinelmer.com
or
Mario
Fante, 781-663-5602
Corporate Public Relations Manager
mario.fante@perkinelmer.com
Source: PerkinElmer, Inc.
News Provided by Acquire Media